LEUPROLIDE ACETATE | N021088 | ORTHO MCNEIL JANSSEN PHARMACEUTICAL INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 2 | Active | Jonsson Comprehensive Cancer Center | 28 | 2021-03-17 → 2028-01-01 | |
| Phase 2/3 | Active | Sir Mortimer B. Davis - Jewish General Hospital | 102 | 2016-10 → 2041-08 | |
| Phase 3 | Active | Alliance for Clinical Trials in Oncology | 788 | 2007-05-08 → 2030-10 | |
| Phase 1/2 | Active | University of Michigan Rogel Cancer Center | 102 | 2020-11-06 → 2029-05 | |
| Phase 2 | Active | Fondazione Sandro Pitigliani | 116 | 2018-12-27 → 2025-11-27 | |
| Phase 3 | Active | Pfizer | 1,068 | 2014-12-17 → 2026-09-19 | |
| Phase 2 | Active | Mark Stein | 26 | 2019-05-16 → 2028-04 | |
| Phase 2 | Active | M.D. Anderson Cancer Center | 310 | 2013-02-05 → 2027-02-01 | |
| Phase 2 | Active | City of Hope Medical Center | 29 | 2006-07-18 → 2027-02-15 | |
| Phase 1 | Active | Thomas Jefferson University | 25 | 2014-04-02 → 2040-01-01 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
15 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Jan 20, 2011 | SUPPL -25 | View Letter (PDF) |
| Sep 22, 2005 | SUPPL -22 | View Letter (PDF) |
| Sep 14, 2005 | SUPPL -7 | View Letter (PDF) |
| Aug 15, 2003 | SUPPL -15 | View Letter (PDF) |
| Mar 3, 2000 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.